New hope for advanced breast cancer: SKB264 trial launches

NCT ID NCT06081959

Recruiting now Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests a new drug called SKB264 against standard chemotherapy in 376 people with advanced HR+/HER2- breast cancer that has worsened after at least one chemotherapy. The goal is to see if SKB264 can slow cancer growth or improve survival. Participants are randomly assigned to receive SKB264 or one of several standard chemotherapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SKB264 (a drug given by IV)
What this could lead to: If it works, this could offer a new treatment option for people with advanced HR+/HER2- breast cancer who have run out of standard chemotherapy choices.
What could go wrong: This is a phase 3 trial, but it's still experimental. SKB264 may not prove better than existing treatments, and side effects are possible. Results may take years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+/HER2- BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Science
RECRUITING

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.